Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine

J Gen Virol. 2003 Feb;84(Pt 2):361-368. doi: 10.1099/vir.0.18738-0.


A novel, experimental subunit human immunodeficiency virus (HIV) vaccine, SFV.HIVA, was constructed. This consists of Semliki Forest virus (SFV), which is a suitable vaccine vector for use in humans, and a passenger gene encoding HIVA, which is an immunogen derived from HIV-1 clade A that is being currently tested in clinical trials of combined DNA- and modified vaccinia virus Ankara (MVA)-vectored vaccines in Oxford (UK) and Nairobi (Kenya). In the mouse, the SFV.HIVA vaccine was highly immunogenic for T cell-mediated immune responses and induced T cell memory that lasted for at least 6 months. SFV.HIVA was also compared to the vaccines currently used in the clinical trials and was shown to be as effective in T cell induction as pTHr.HIVA DNA but less immunogenic than MVA.HIVA. When tested in a prime-boost regimen, SFV.HIVA-induced responses could be boosted by MVA.HIVA. This work is a part of a long-term effort to build a panel of subunit vaccines expressing a common immunogen, which will allow both a direct comparison of various vaccine vectors and combined vaccination regimens in humans and provide more flexibility and/or a potential optimization of vaccinations for individuals based on their pre-existing anti-vector immunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines*
  • Animals
  • CD8-Positive T-Lymphocytes / immunology
  • Cell Line
  • Drug Design*
  • Female
  • Genetic Vectors*
  • HIV Infections / immunology
  • HIV Infections / prevention & control
  • HIV-1 / classification
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Humans
  • Immunization
  • Immunization Schedule
  • Immunization, Secondary
  • Mice
  • Mice, Inbred BALB C
  • Semliki forest virus / genetics*
  • Vaccines, Synthetic / immunology
  • Vaccinia virus / genetics
  • Vaccinia virus / immunology


  • AIDS Vaccines
  • Vaccines, Synthetic